Literature DB >> 32002622

Fatal Lung Toxicity After Intralesional Bleomycin Sclerotherapy of a Vascular Malformation.

Alexander L Cho1, Sharon C Kiang2,3, Jonathan Lodenkamp4, William T H Tritch4, Roger T Tomihama4.   

Abstract

Although there has been increased utilization of bleomycin in the treatment of low-flow vascular malformations in children, previous studies report minor adverse effects limited to skin changes/necrosis and flu-like symptoms (Horbach et al. in J Plast Reconstr Aesthet Surg 69(3):295-304, 2016). However, there have been rare reported cases of pulmonary injury observed in children after bleomycin intralesional administration. We report a case of fatal lung toxicity in a 15-month-old girl after injecting 7 units of bleomycin into a left cheek macrocystic lymphatic malformation. 1 week after therapy, she developed respiratory distress with imaging findings of pneumothorax and diffuse alveolar damage. Despite extensive management and resuscitative efforts of presumed pneumonitis, further decline resulted in death via respiratory failure. Early detection of pulmonary toxicity would allow prompt therapy and could avoid significant pulmonary damage.

Entities:  

Keywords:  Bleomycin; Pediatric; Pulmonary toxicity; Sclerotherapy

Mesh:

Substances:

Year:  2020        PMID: 32002622     DOI: 10.1007/s00270-020-02420-w

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  2 in total

1.  Long term outcomes of transcutaneous non-image guided bleomycin sclerotherapy in orbital/adnexal lymphatic malformations: a protocol-based management in 69 eyes.

Authors:  Tarjani Vivek Dave; Bejjanki Kavya Madhuri; Srujana Laghmisetty; Devjyoti Tripathy; Swathi Kaliki; Suryasnata Rath; Samir Mohapatra; Akruti Desai; Anasua Ganguly Kapoor
Journal:  Eye (Lond)       Date:  2021-04-20       Impact factor: 3.775

2.  Intraoperative Anaphylaxis Following Injection of a Bleomycin-Gelatin Solution for Sclerotherapy.

Authors:  Laura Roberts; Leah Braswell; Gregory Maves; Kimberly Stumpf; Margaret Redmond; Joseph D Tobias
Journal:  J Med Cases       Date:  2022-03-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.